Ultrasensitive ctDNA Monitoring Predicts Breast Cancer Recurrence & Guides Treatment

New research is refining the employ of circulating tumor DNA (ctDNA) monitoring to assess treatment response and predict recurrence in early breast cancer, particularly in HER2-positive and triple-negative subtypes. Kefah Mokbel, Chair of Breast Cancer Surgery at the London Breast Institute, recently highlighted findings from a study published in the Journal of Clinical Oncology that demonstrate the potential of ultrasensitive ctDNA detection to identify minimal residual disease and guide personalized treatment strategies.

The study, titled “The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease,” enrolled 227 patients undergoing neoadjuvant therapy – treatment given before surgery – for early breast cancer. Researchers were able to evaluate 220 patients for pathological complete response (pCR), meaning no cancer was found in the tissue after neoadjuvant treatment. The study population was split relatively evenly between two aggressive subtypes: 48% had HER2-positive breast cancer (105 patients), and 52% had triple-negative breast cancer (115 patients). The full article details the methodology and results.

Understanding Pathological Complete Response and ctDNA

41% of patients (91 out of 220) achieved a pCR. Within the subtypes, the pCR rate was 50% for HER2-positive cancers (52/105) and approximately 41% for triple-negative breast cancer. However, the study’s most significant findings relate to ctDNA – fragments of tumor DNA that circulate in the bloodstream. Detecting ctDNA, even in very small amounts, can indicate the presence of remaining cancer cells after treatment.

Using a highly sensitive, tumor-informed sequencing approach, investigators detected ctDNA in 96% of baseline (pre-treatment) samples (91 out of 95). The median variant allele fraction – the proportion of ctDNA compared to normal DNA – was 0.15%, with a detection range from 0.0011% to 38.7%. This demonstrates the remarkable sensitivity of modern assays, capable of identifying extremely low levels of tumor DNA in the blood. This level of sensitivity is crucial for detecting minimal residual disease (MRD), which refers to cancer cells that remain after treatment but are not detectable by conventional imaging.

ctDNA Dynamics Predict Recurrence Risk

The study revealed that the changes in ctDNA levels during treatment provided valuable prognostic information. Specifically, persistent ctDNA detected during the second cycle of treatment was associated with a significantly higher risk of distant recurrence (p=0.047). Perhaps even more strikingly, ctDNA detected recurrence before clinical or radiological relapse in 100% of the cases observed. The median lead time – the time between ctDNA detection of recurrence and clinical confirmation – was approximately 14 months (417 days). This suggests ctDNA monitoring could offer an earlier warning system than traditional surveillance methods.

This early detection is particularly important because it allows for potential intervention before the cancer spreads further. Currently, standard surveillance relies on imaging techniques like mammograms and scans, which may not detect recurrence until it’s more advanced. The ability to identify recurrence months or even a year earlier could significantly improve treatment outcomes.

Implications for Personalized Breast Cancer Treatment

These findings suggest several potential clinical applications for ctDNA monitoring in early breast cancer. Beyond early identification of MRD and prediction of recurrence risk, ctDNA monitoring could lead to more personalized treatment strategies. For patients with persistent molecular disease – meaning ctDNA remains detectable during treatment – treatment escalation might be considered. This could involve adding chemotherapy, switching to a different drug, or exploring clinical trials. Conversely, for patients with rapid molecular clearance – meaning ctDNA disappears quickly during treatment – therapy de-escalation might be an option, potentially reducing unnecessary side effects.

Kefah Mokbel’s post on LinkedIn emphasizes that these findings need to be validated in larger, prospective trials before ctDNA monitoring becomes standard practice. However, the study adds to a growing body of evidence supporting the use of liquid biopsies – blood tests that analyze tumor-related material – as a complement to traditional clinical and pathological assessments.

The Role of the CXCR4-SDF-1 Axis in Recurrence

Related research, as highlighted in a PubMed article, explores the potential biological mechanisms behind locoregional recurrence – cancer returning in the same area as the original tumor. This research, also led by Kefah Mokbel, proposes a “breast-homing” mechanism involving the CXCR4-SDF-1 axis. This suggests that reactivated circulating tumor cells may be attracted back to the breast tissue, potentially explaining why recurrence is more common in patients who undergo breast-conserving surgery compared to mastectomy. Understanding these biological processes is crucial for developing more effective prevention and treatment strategies.

What’s Next for ctDNA Monitoring?

The field of ctDNA monitoring is rapidly evolving. Ongoing research is focused on refining the sensitivity and specificity of ctDNA assays, identifying the optimal timing for monitoring, and developing standardized protocols for data interpretation. Several clinical trials are underway to evaluate the impact of ctDNA-guided treatment decisions on patient outcomes. These trials will be critical for determining whether ctDNA monitoring can truly improve the lives of individuals diagnosed with early breast cancer. Further investigation into the interplay between ctDNA dynamics and the biological factors driving recurrence, such as the CXCR4-SDF-1 axis, will also be essential.